Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2014-08-27Clinical Trial Update: A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib [Phase 1, Phase 2]
A Phase 1/2 single-agent trial of vemurafenib in multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-07-11Clinical Trial Update: Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma [Phase 2]
A Phase 2 trial evaluating a carfilzomib/SAHA combination with high-dose gemcitabine/busulfan/melphalan and autologous stem cell transplant …
-
CLINICAL_TRIALS withdrawal · 2014-05-12Clinical Trial Update: Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM) [Phase 2]
A Phase 2 trial of SDX-101 (R-Etodolac) for relapsed or refractory multiple myeloma has been terminated.
-
CLINICAL_TRIALS withdrawal · 2013-07-10Clinical Trial Update: Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma [Phase 2]
A Phase 2 trial evaluating arsenic trioxide, ascorbic acid, dexamethasone, and thalidomide in multiple myeloma has been withdrawn. The study…
-
CLINICAL_TRIALS withdrawal · 2013-07-10Clinical Trial Update: Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]
A Phase 2 clinical trial evaluating a combination of melphalan, arsenic trioxide, and ascorbic acid in relapsed or refractory multiple myelo…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2013-06-21Clinical Trial Update: Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma [Phase 2]
This document reports that a Phase 2 trial of autologous stem cell transplantation with maintenance therapy for multiple myeloma has been te…
-
CLINICAL_TRIALS withdrawal · 2013-04-05Clinical Trial Update: Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts [Phase 2]
A Phase 2 trial evaluating ex-vivo depletion of myeloma cells from peripheral blood progenitor cell grafts in multiple myeloma has been with…
-
CLINICAL_TRIALS withdrawal · 2013-04-02Clinical Trial Update: Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer [NA]
Clinical trial evaluating Aprepitant and Ondansetron for opioid-induced nausea and vomiting in cancer patients; the study was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-02-20Clinical Trial Update: Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma [Phase 1]
The phase 1 trial of dovitinib in combination with bortezomib and dexamethasone for relapsed/refractory multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-02-15Clinical Trial Update: Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies [Phase 1, Phase 2]
Clinical trial update notes the withdrawal of a Phase 1/2 study evaluating antimicrobial versus saline solutions to maintain catheter patenc…
-
CLINICAL_TRIALS withdrawal · 2013-01-28Clinical Trial Update: A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [Phase 3]
A Phase 3 trial of siltuximab or placebo with Velcade and dexamethasone in relapsed or refractory multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-01-10Clinical Trial Update: IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus [Phase 2]
A Phase 2 trial evaluating pasireotide lar in combination with everolimus for multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-10-02Clinical Trial Update: Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer [Phase 2]
Phase 2 study of busulfan and fludarabine conditioning before donor stem cell transplant for hematologic cancers has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-09-07Clinical Trial Update: Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients [Phase 2]
The Phase 2 trial NCT01269203 investigating an NF-kB inhibitor to reduce symptoms during maintenance therapy in multiple myeloma has been wi…
-
CLINICAL_TRIALS withdrawal · 2012-05-11Clinical Trial Update: Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma [Phase 2]
A Phase 2 trial evaluating the combination of vorinostat (Zolinza) with Doxil and bortezomib for relapsed/refractory multiple myeloma has be…
-
CLINICAL_TRIALS withdrawal · 2012-03-26Clinical Trial Update: A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma [Phase 2]
A Phase 2 trial of GSK2110183 in proteasome inhibitor refractory multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-02-23Clinical Trial Update: Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy [Phase 1]
Phase 1 safety study of a PD-L1 inhibitor sponsored by Bristol-Myers Squibb has been withdrawn. The study targeted hematologic malignancies …
-
CLINICAL_TRIALS withdrawal · 2012-01-12Clinical Trial Update: Vertebral Augmentation With Kyphoplasty vs Nonsurgical Mgmt for Vertebral Body Compression Fractures [NA]
This clinical trial update shows the study comparing kyphoplasty versus non-surgical management for vertebral body compression fractures in …
-
CLINICAL_TRIALS withdrawal · 2011-05-03Clinical Trial Update: A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD) [Phase 2]
A Phase 2 pilot trial of melphalan, bortezomib, thalidomide, and dexamethasone (MEL-VTD) for multiple myeloma has been withdrawn from the st…
-
CLINICAL_TRIALS withdrawal · 2010-11-10Clinical Trial Update: A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies [Phase 2]
A Phase 2 trial of a novel MUC1-expressing vaccine for tumor malignancies has been withdrawn, including multiple myeloma as an indicated con…
-
CLINICAL_TRIALS withdrawal · 2009-04-23Clinical Trial Update: Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma [Phase 1]
A Phase I trial evaluating P276-00 for safety and efficacy in subjects with multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2008-10-28Clinical Trial Update: A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating ATN-224 in combination with Bortezomib for multiple myeloma has been terminated.